SCHEMBL2012183

SCHEMBL2012183

CCOC(=O)COc1ccc(C(=O)CNC(=O)OC(C)(C)C)c(O)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.55
HSD17B10 Q99714 3/20 0.47
TP53 P04637 3/20 0.47
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
LMNA P02545 1/20 0.47
GAA P10253 3/20 0.42
KDM4E B2RXH2 2/20 0.42
NPC1 O15118 2/20 0.41
MAPK1 P28482 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
MAPT P10636 4/20 0.40
RAB9A P51151 2/20 0.40
ALDH1A1 P00352 1/20 0.40
GLA P06280 1/20 0.40
PPARD Q03181 1/20 0.40
PDE3B Q13370 1/20 0.39
PDE3A Q14432 1/20 0.39
P2RY12 Q9H244 1/20 0.39
ALDH2 P05091 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2011135 0.91 HPGD (0.47) HPGDHSD17B10TP53KMT2AMEN1
SCHEMBL2012428 0.90 HPGD (0.45) HPGDHSD17B10TP53KMT2AMEN1
SCHEMBL2009782 0.88 HPGD (0.48) HPGDTP53KMT2AMEN1LMNA
SCHEMBL2008992 0.87 HPGD (0.43) HPGDHSD17B10TP53KMT2AMEN1
SCHEMBL2014181 0.86 HPGD (0.42) HPGDHSD17B10TP53KMT2AMEN1
SCHEMBL2011241 0.82 PDE5A (0.43) HPGDHSD17B10KMT2AMEN1LMNA
SCHEMBL2011477 0.81 GAA (0.40) HPGDKMT2AMEN1LMNAGAA
SCHEMBL2010297 0.81 HMGCR (0.39) HPGDKMT2AMEN1GAAMAPK1
SCHEMBL2011589 0.80 CASP7 (0.40) HPGDHSD17B10KMT2AMEN1LMNA
SCHEMBL2011021 0.80 CASP7 (0.39) HPGDHSD17B10KMT2AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964628-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-06-21 US disclosed
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-10-07 US disclosed
US-7759387-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-07-20 US disclosed
US-20070021489-A1 Fibrinogen receptor antagonists and their use NICHOLAS PIRAMAL INDIA LIMITED (IN) 2007-01-25 US disclosed
EP-1677783-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE Nicholas Piramal India Limited (IN) 2006-07-12 EP disclosed
WO-2005035495-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE NICHOLAS PIRAMAL INDIA LIMITED (IN) 2005-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE FGB, F13B, F2 HPGD 1551/4885HSD17B10 3132/4885TP53 1890/4885
US-20070021489-A1 Fibrinogen receptor antagonists and their use FGB, F13B, F2 HPGD 1551/4885HSD17B10 3132/4885TP53 1890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.